免疫疗法
临床试验
肿瘤微环境
癌症免疫疗法
过继免疫治疗
细胞疗法
祖细胞
医学
生物
肿瘤科
免疫学
干细胞
内科学
免疫系统
遗传学
作者
Mrinal K. Ghosh,Sunny Kumar,Sabana Begam,Sayani Ghosh,Malini Basu
出处
期刊:Life Sciences
[Elsevier]
日期:2024-08-28
卷期号:356: 123018-123018
标识
DOI:10.1016/j.lfs.2024.123018
摘要
GBM is the most common, aggressive, and intracranial primary brain tumor; it originates from the glial progenitor cells, has poor overall survival (OS), and has limited treatment options. In this decade, GBM immunotherapy is in trend and preferred over several conventional therapies, due to their better patient survival outcome. This review explores the clinical trials of several immunotherapeutic approaches (immune checkpoint blockers (ICBs), CAR T-cell therapy, cancer vaccines, and adoptive cell therapy) with their efficacy and safety. Despite significant progress, several challenges (viz., immunosuppressive microenvironment, heterogeneity, and blood-brain barrier (BBB)) were experienced that hamper their immunotherapeutic potential. Furthermore, these challenges were clinically studied to be resolved by multiple combinatorial approaches, discussed in the later part of the review. Thus, this review suggests the clinical use and potential of immunotherapy in GBM and provides the holistic recent knowledge and future perspectives.
科研通智能强力驱动
Strongly Powered by AbleSci AI